Previous 10 | Next 10 |
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA PR Newswire TOKYO and CAMBRIDGE, Mass. , March 31, 2024 /PRNewswir...
2024-03-30 12:13:00 ET The Health Care Select Sector SPDR Fund ETF ( NYSEARCA: XLV ), tracking the healthcare companies under S&P 500, rose 8.32% in the first quarter of 2024, lagging slightly behind the broader S&P 500 index which rose 10.16%.... Read the full article...
A look at the top 10 most actives in the United States C3is Inc. (CISS) rose 36.6% to $0.0481 on volume of 589,492,515 shares Nikola Corporation (NKLA) rose 9.5% to $0.8139 on volume of 120,009,646 shares Tesla Inc. (TSLA) rose 2.9% to $177.67 on volume of 112,332,335 shares Direxion Da...
A look at the top 10 most actives in the United States C3is Inc. (CISS) rose 50.9% to $0.0531 on volume of 188,520,681 shares OpGen Inc. (OPGN) rose 64.8% to $0.783 on volume of 46,448,042 shares KULR Technology Group Inc. (KULR) rose 26.2% to $0.4102 on volume of 30,163,025 shares Tesl...
2024-03-22 08:50:49 ET More on Biogen, Eisai Co., Ltd., etc. Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Eisai: All About Lenvima And Leqembi Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen chief medical o...
2024-03-20 09:00:32 ET More on Labcorp Laboratory Corporation of America Holdings (LH) Q4 2023 Earnings Call Transcript Laboratory Corporation of America Holdings 2023 Q4 - Results - Earnings Call Presentation Labcorp introduces weight loss management portfolio ...
2024-03-19 14:16:03 ET Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days Conference March 19, 2024 10:00 AM ET Company Participants Priya Singhal - Head of Development & Interim Chief Medical Officer Conference Call Participants Paul Matteis - Stifel ...
2024-03-19 13:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-15 16:08:53 ET More on Biogen Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript AbCellera ga...
NEW YORK, NY / ACCESSWIRE / March 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ:BIIB). Investors who purchased Biogen Inc. securities are encouraged to obtain additional informat...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...